Grilled Cheese

ExploreLog inSign up
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-15 18:51:49 EDT

PhotosVideosAllPeople
LatestRanked
@theneurocurious.bsky.socialOct 15, 2026, 8:03 PM

🌟 Exciting news! 🎉 Our latest freebie in Spanish is live and ready for you! Don't miss out—grab yours now! 👉 Download here: https://tr.ee/zM14ec 

#freebie #neurology #brainhealth #sleep #spanish

Photo, no description
@mgnews.bsky.socialOct 15, 2026, 7:31 PM

A gentle reminder: https://bit.ly/4qNtHF9

#MyastheniaGravisNews #Bionews #ChronicIllnessCommunity #MGStrong #MGSupport #InvisibleIllness #ChronicIllnessAwareness #MGWarrior #Neurology #Neurologist

@gregoryai.bsky.socialOct 15, 2026, 5:50 PM

New clinical trial
A Prospective Multimodal Cohort Study of Cognitive Impairment and Progression From Mild Cognitive Impairment to Dementia

#ClinicalTrials #AlzheimersDisease #EndAlz #Neurology

@gregoryai.bsky.socialOct 15, 2026, 5:40 PM

New clinical trial
Characteristics and Mechanism Research of Probable Alzheimer's Disease With Behavioral and Psychological Symptoms of Dementia With Negative Plasma p-tau217

#ClinicalTrials #AlzheimersDisease #EndAlz #Neurology

@neurohosp.bsky.socialOct 15, 2026, 4:24 PM

Congratulations to NHS Board Member Dr. Vanja Douglas on receiving the @aaln-leaders.bsky.social Faculty Leadership Award! 🎉

Nominated by neurology chairs, this honor recognizes leaders moving the field forward. A proud moment for neurohospital medicine.

#Neurohospitalist #Neurology #NeuroSky

Photo, no description
@journalneurooph.bsky.socialOct 15, 2026, 4:03 PM

Quantification of Mitochondrial Stress in Nonarteritic Anterior Ischemic Optic Neuropathy Using Flavoprotein Fluorescence Imaging: Journal of Neuro-Ophthalmology
Article link: bit.ly/JNO_NAION_mi...
#brain #eye #vision #research #Neurology #NeuroOphth #Ophthalmology #Medicine #NAION #EyeStroke

Photo, no descriptionPhoto, no description
@intechopen.comOct 15, 2026, 1:28 PM

Osmotic demyelination syndrome can be difficult to recognise, with potentially life-threatening consequences.

Authors from Yale University explore its risk factors, prevention and emerging treatments.

Read: bit.ly/3TZxK5K

#IntechOpen #OpenAccess #Neurology #NeurocriticalCare

Photo, no description
@neurotherapytdy.bsky.socialOct 15, 2026, 1:27 PM

Researchers evaluated a natural language processing model designed to identify #migraine from #primarycare clinical notes, highlighting the potential for AI-assisted review to flag cases that may otherwise be misdiagnosed or missed.#Neurology #Medicine
www.docwirenews.com/post/ai-assi...

@palamedesreport.orgOct 15, 2026, 1:00 PM

Ofatumumab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Nationwide Cohort Study.
Neurology

This week in Multiple Sclerosis and Neuroimmunology: palamedesreport.org/this-week/multiple-sclerosis
pubmed.ncbi.nlm.nih.gov/42832743

#MedSky #neurology #multiplesclerosis

This week in Multiple Sclerosis and Neuroimmunology: Ofatumumab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Nationwide Cohort Study. Neurology. AI-generated. Verify against the paper. In Danish registry patients with relapsing-remitting MS, ofatumumab was associated with a marginally higher annualized relapse rate than ocrelizumab (rate ratio 1.65, 95% CI 1.09-2.50, p = 0.018), though ARRs were very low with both. Design: Observational cohort study using the Danish Multiple Sclerosis Registry; 1,870 patients initiating treatment January 2022 to November 2025; inverse probability of treatment weighting on propensity scores; intention-to-treat main analyses with per-protocol analyses; median follow-up 2.0 years (IQR 1.3-2.7) ofatumumab, 2.5 years (1.3-3.4) ocrelizumab. Class II evidence. Population: Patients with relapsing-remitting MS: 485 started ocrelizumab (mean age 41.1 years, 65.2% female) and 1,385 started ofatumumab (mean age 41.3 years, 72.0% female). Biomarker status not reported. Ranked by PubMed attention — the views of everyone using PubMed — not by quality, importance or correctness.
@gregoryai.bsky.socialOct 15, 2026, 7:00 AM

Multiple sclerosis (MS) is a persistent immune-mediated condition marked by neuroinflammation, demyelination, and ongoing neurological impairment. Although there have been advancements in therapies aimed at modifying the disease, signifi...
#MSchat #MS #Neurology #MultipleSclerosis #NeuroSky #MedSky

@gregoryai.bsky.socialOct 15, 2026, 7:00 AM

New clinical trial
Co-Designing and Testing the Feasibility of a Gamified AI Medical Yoga App for Home-Based Cancer Rehabilitation

#ClinicalTrials #AlzheimersDisease #EndAlz #Neurology

@tenuretracker.bsky.socialOct 14, 2026, 8:22 PM

Yale University is hiring:
Assistant/Associate Professor in General Neurology

#professor #medicine #neurology

@biovie.bsky.socialOct 14, 2026, 8:21 PM

Results from two BioVie studies - ADDRESS-LC Phase 2 trial in #LongCOVID & SUNRISE-PD Phase 2 trial of bezisterim in #ParkinsonsDisease - will be presented as posters at #ANA2026 being held Oct 17–20 in San Diego, CA

Details: investors.bioviepharma.com/news/news-de...
#Neuroinflammation #Neurology

American Neurological Association Annual Meeting Poster Presentations LEFT Sunday, October 18 5:30 - 7:00 PM Results of a Double-Blind Placebo-Controlled Study of the Efficacy and Safety of Bezisterim (NE3107) in Long COVID (ADDRESS-LC) Authors: Penelope Markham, Michael J. Peluso, Christopher Reading, Clarence Ahlem, Stephen O’Quinn, Navid A. Samad, Jeffrey Zhang, Joseph M. Palumbo RIGHT Monday, October 19 5:30 - 7:00 PM Bezisterim (NE3107) in Early Parkinson’s Disease (SUNRISE-PD): Initial Results and Observations From a Phase 2 Hybrid Design Trial Authors: Joseph Palumbo; Clarence Ahlem; Christopher L. Reading; Stephen O’Quinn; Jeffrey Zhang; Mark Stacy
@gregoryai.bsky.socialOct 14, 2026, 5:50 PM

New clinical trial
An Open-Label Extension and Safety Monitoring Study of Patients With Symptomatic Transthyretin Cardiomyopathy Who Have Completed the Phase II Study AG10-201

#ClinicalTrials #AlzheimersDisease #EndAlz #Neurology

@gregoryai.bsky.socialOct 14, 2026, 5:40 PM

New clinical trial
A Multicenter, Phase 2, Open-Label, Randomized, Crossover Comparison of Two Formulations of Flutemetamol F 18 Injection

#ClinicalTrials #AlzheimersDisease #EndAlz #Neurology

@runningmadprof.bsky.socialOct 14, 2026, 5:27 PM

Our European guidelines on diagnosing and managing infectious encephalitis in adults are now published in the European Journal of Neurology.

Thanks to all colleagues involved!

onlinelibrary.wiley.com/doi/10.1111/...

#Encephalitis #Neurology

@medliveofficial.bsky.socialOct 14, 2026, 3:29 PM

Many patients with gMG still face residual symptoms and steroid burden. ▶️ Watch this on-demand program exploring treat-to-target care, patient goals, and emerging RNAi-based complement modulation.

Watch: vist.ly/5ndfk

#gMG #Neurology #MedEd

MedliveCrossfire session on gMG therapies with two speakers' portraits.
@neurotherapytdy.bsky.socialOct 14, 2026, 1:59 PM

New findings suggest gestational #diabetes does not independently increase offspring #autism risk after adjustment for maternal and #pregnancy-related factors.#Neurology
www.docwirenews.com/post/no-stro...

@neurologylive.bsky.socialOct 14, 2026, 1:25 PM

🧠 Could intranasal nerve growth factor help address cerebral palsy-related brain injury❓

Dompé has enrolled the first patient in the phase 2 Galassia trial testing intranasal cenegermin in ~60 children aged 2–6 years with spastic CP

Read More 👉 www.neurologylive.com/view/domp-be...
#Neurology

@palamedesreport.orgOct 14, 2026, 1:00 PM

Acute Imbalance Syndrome vs Acute Vestibular Syndrome: Clinical and Topographical Differentiation.
Neurology

This week in Stroke and Vascular Neurology: palamedesreport.org/this-week/stroke
pubmed.ncbi.nlm.nih.gov/42848973

#MedSky #neurology #stroke

This week in Stroke and Vascular Neurology: Acute Imbalance Syndrome vs Acute Vestibular Syndrome: Clinical and Topographical Differentiation. Neurology. AI-generated. Verify against the paper. Among 75 ED patients with MRI-proven stroke causing acute vertigo/dizziness or imbalance, 58.7% had acute imbalance syndrome (AIS, no spontaneous nystagmus) versus 38.7% with acute vestibular syndrome (AVS), and the two phenotypes mapped to different cerebellar lesion territories. Design: Prospective emergency department cohort study at LMU Hospital; 75 patients with MRI-proven stroke-related acute vertigo/dizziness or imbalance; lesions mapped in Montreal Neurological Institute space with structural disconnectome mapping and multivariate support-vector-regression lesion symptom mapping; follow-up not reported. Population: Patients presenting to the ED with acute vertigo/dizziness or imbalance and MRI-proven stroke; age 65.7 ± 13.3 years, 40% female. Biomarker status not applicable/not reported. Ranked by PubMed attention — the views of everyone using PubMed — not by quality, importance or correctness.
Load more